about
Oral lichen planus: An overviewAccess and management of HIV-related diseases in resource-constrained settings: a workshop report.HIV protease inhibitors block oral epithelial cell DNA synthesis.Oral Health Status and Oromucosal Lesions in Patients Living with HIV/AIDS in India: A Comparative Study.Oral lesions of HIV disease and HAART in industrialized countries.Gastrointestinal side effects of drugs.Adverse effects of antiretroviral therapy: focus on orofacial effects.Effects of long-term use of HAART on oral health status of HIV-infected subjects.Relationship of long-term highly active antiretroviral therapy on salivary flow rate and CD4 Count among HIV-infected patients.Lichenoid contact reaction to eugenol presenting as oral lichen planusAdverse drug reactions in the orofacial region.Impact of highly active antiretroviral therapy on salivary flow in patients with human-immuno deficiency virus disease in Southern India.Effect of HAART on salivary gland function in the Women's Interagency HIV Study (WIHS)Comparison of epigenetic profiles of human oral epithelial cells from HIV-positive (on HAART) and HIV-negative subjectsOral complications of HIV disease.Differences in Salivary Flow Level, Xerostomia, and Flavor Alteration in Mexican HIV Patients Who Did or Did Not Receive Antiretroviral Therapy.Antiretroviral therapy: effects on orofacial health and health care.Oral health considerations in HIV-infected children.Oral lichen planus: a literature review and update.Perception of taste in HIV-positive individuals in treatment antiretroviral: results of a case-control study.HIV nucleoside reverse transcriptase inhibitors efavirenz and tenofovir change the growth and differentiation of primary gingival epithelium.Effect of the HIV nucleoside reverse transcriptase inhibitor zidovudine on the growth and differentiation of primary gingival epitheliumEffect of the HIV protease inhibitor amprenavir on the growth and differentiation of primary gingival epithelium.The HIV protease inhibitor lopinavir/ritonavir (Kaletra) alters the growth, differentiation and proliferation of primary gingival epithelium.Antiretroviral Drug-Associated Oral Lichenoid Reaction in HIV Patient: A Case Report.Switching to darunavir/ritonavir 800/100 mg once-daily containing regimen maintains virological control in fully suppressed pre-treated patients infected with HIV-1.Sore or Swollen Lips Part 2: Systemic Causes.
P2860
Q27022934-131D68BE-6934-48B5-A90C-9F71AB4C7B96Q30387272-43A07AB3-AFE5-47C8-A4C4-C99539F94C0BQ33639842-F44F2BFA-C5A1-4511-B1A5-ED258A775293Q34151584-BC99371F-FC41-4FE9-8FFD-344B9D95C9D1Q34521587-1600F560-ECAC-4AF4-BAB7-DADAC756F67EQ35194370-46A864E3-EE6D-4EBA-B685-B150372551A5Q35194451-BCE4AA5B-92A0-4370-B986-F94151604018Q35552903-FA913825-75C4-437D-A981-6B3E1F7081F4Q35672720-9C2F2F7F-2FB5-454C-95BC-20E951988E4BQ35776969-0B5EBC15-A16D-4543-A2F8-99A092F5233FQ35850842-820AB18A-E22D-4087-A147-2A12BB0575BFQ36941901-24680E12-BB5D-4487-B195-C6EF292403F9Q37100683-9A4E7D28-159B-422A-9CA2-A13CE531356EQ37192629-FD16BCD0-0F6C-4172-84AC-FAEAFB9115ACQ37222240-84BB2A8C-92DB-4D6E-9C09-B9C71704947AQ37433185-EEBEC7CB-6951-449C-AAE0-9C6678E17602Q38093238-C2244DCD-9A6E-4E2B-B414-28FB27EFF205Q38113153-B7ACAD59-92B8-414C-B204-4D165092ACA7Q38878721-91B4A5CC-AD1B-4F9F-897C-DEBBE3C1BD4DQ40700368-9D0E2C3C-19EC-462C-8B5C-4A244B17C506Q41999400-1B655666-3B79-4CFD-AA9C-736DDEA14CD8Q42067473-647D1ABA-665C-4073-92A7-95DDAFF1B21DQ42116942-88637B51-2A0B-4718-B174-6E2C9D59F3B9Q42576594-8460E176-633B-49D6-9271-0F2A0FADF3AAQ42703930-7700DAB0-1052-4846-8625-7011D1188FB1Q46106006-C27FEC19-E3F8-4552-B6FE-EC268C4283EFQ49858648-B8E81189-3048-42B2-8377-E0D5004FCA23
P2860
description
2001 nî lūn-bûn
@nan
2001 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Orofacial effects of antiretroviral therapies.
@ast
Orofacial effects of antiretroviral therapies.
@en
Orofacial effects of antiretroviral therapies.
@nl
type
label
Orofacial effects of antiretroviral therapies.
@ast
Orofacial effects of antiretroviral therapies.
@en
Orofacial effects of antiretroviral therapies.
@nl
prefLabel
Orofacial effects of antiretroviral therapies.
@ast
Orofacial effects of antiretroviral therapies.
@en
Orofacial effects of antiretroviral therapies.
@nl
P2860
P1433
P1476
Orofacial effects of antiretroviral therapies.
@en
P2093
P2860
P304
P356
10.1034/J.1601-0825.2001.70401.X
P577
2001-07-01T00:00:00Z